advanceCOR GmbH is a clinical drug developing company based in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for the personalized treatment of heart and vascular diseases (“precision medicine”). advanceCOR´s activities and experiences comprise all steps from research to drug development and commercialization. advanceCOR owns a quite extensive product pipeline:
- Revacept, a drug to treat acute arterial thrombosis/thromboembolic disease (e. g., myocardial infarction and stroke) showed effects in man ex vivo, and was very well tolerated. A clinical phase II study on stroke or transient ischemic attack (TIA) has revealed beneficial effects for patients who were treated with 120 mg Revacept. Another study by the German centre of cardiovascular diseases (DZHK) on coronary artery disease (CAD) has already recruited all anticipated patients.
- Fusion proteins derived from Revacept which express additional effector features
- Fully human antibody Fab fragments from a cooperation with Morphosys AG which block platelet surface receptors
- cyclic peptides for thyroid disease, including its cardiac and ocular complications
The product developments are being pursued by advanceCOR with all necessary assays (e. g., pharmacokinetics) according to „good laboratory and clinical practice“ (GLP and GCP). The compounds are also being produced in bioreactors at advanceCOR.
All these innovative products were derived from in-house research and development, compounds which had been dismissed by others have not been in-licensed.
The company has secured financing by MIG Fonds, ERP start fonds, High-tech fonds and Bayern Kapital.